Teva Loses 180-Day Exclusivity For Generic Actonel As FDA Stands Firm On Review Delays
This article was originally published in The Pink Sheet Daily
Executive Summary
Mylan’s product launches as FDA tells Teva that the agency’s delay in granting tentative ANDA approval does not prevent forfeiture of exclusivity.
You may also be interested in...
Teva Sues US FDA To Obtain 180-Day Exclusivity For Its Generic Restasis
Complaint challenges agency's revised definition of "first applicant," which does not require notice of Paragraph IV certification to obtain exclusivity.
Teva Sues US FDA To Obtain 180-Day Exclusivity For Its Generic Restasis
Complaint challenges agency's revised definition of "first applicant," which does not require notice of Paragraph IV certification to obtain exclusivity.
US FDA Gives Directions On Navigating Generic 180-Day Exclusivity Maze
Draft guidance sums up agency’s policies for determining exclusivity, clarifies when the clock starts for failure to market.